Medindia

X

Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference

Wednesday, February 20, 2008 General News J E 4
Advertisement
PRINCETON, N.J., Feb. 20 Derma Sciences, Inc.(OTC Bulletin Board: DSCI), a provider of advanced wound care products,announced today that four abstracts detailing the clinical usage of its newlyreleased MEDIHONEY(TM) Wound & Burn Dressings with Active Leptospermum Honeywere accepted for presentation at the upcoming annual American ProfessionalWound Care Association conference, held this year between March 6 - 9 in ForthWorth, Texas. Additionally, the company has announced that the use ofMEDIHONEY(TM) Dressings is a topic on the general session agenda for theconference.

About the product's recognition at the upcoming conference, CEO EdwardQuilty said, "The fact that so many abstracts were developed and accepted at anational conference after only four months on the market speaks volumes to theeffectiveness of the MEDIHONEY(TM) dressings. Based on the response andclinical evidence generated while on the market in Europe over the past twoyears, we had a good sense of what would happen upon our launch in the US andCanada. It is exciting to see the product meeting our very high expectations,and to know that we are contributing to the well-being of many patients whowould otherwise have very few options."

The abstracts include the following:

"Chronic Lower Extremity Ulceration -- Use of a Leptospermum ImpregnatedAlginate to Accelerate Wound Closure", Dr. Matt Regulski, DPM, Toms River Footand Ankle Surgical Associates, New Jersey.

"Clinical Application of Absorbent Calcium Alginate Dressing Pads,Containing Manuka (Leptospermum) Honey, in Infected Lower Extremity VenousUlcers", Dr. Paul Kesselman, DPM, Brooklyn, NY

"Favorable Treatment Outcomes of Chronic Leg Ulcers with the Use of a NewLeptospermum Honey Alginate Dressing", Dr. Paul A. Ligouri, MD and Kim L.Peters, RN, CWS, Whittier Rehabilitation Hospital, Haverhill, MA.

"Utilizing Leptospermum Honey Alginate in Treatment of Recalcitrant LowerExtremity Ulcers", Dr. Steven J. Kavros, DPM, Mayo Clinic, Rochester, MN.

In addition to these presentations, the first topic on the conference'sgeneral session agenda following the keynote address will be "MEDIHONEY(TM):An Update on the Newly Approved Natural Approach to Chronic Wounds", to bepresented by Dr. Robert Frykberg, DPM, FAPWCA, MPH, Chief of Podiatry, Carl T.Hayden VA Medical Center in Phoenix, AZ. In this session Dr. Frykberg will beproviding an update on his continuing case series related to the treatment ofrecalcitrant diabetic foot ulcers with MEDIHONEY(TM) dressings, firstpresented at the Clinical Symposium on Advances in Skin and Wound Care lastOctober.

MEDIHONEY is the first FDA-cleared honey-based dressing for use on chronicwounds and burns, and is the only FDA-cleared honey-based product currentlycommercialized. Its key ingredient, Active Leptospermum Honey, has been shownto be effective in a variety of wounds and burns, and was recently the focusof two positive large scale randomized controlled studies on leg ulcers.After four months on the market, the company has made the decision to expandits sales force to meet the high demand for this unique wound care device.

About Derma Sciences

Derma Sciences is a manufacturer and marketer of advanced wound-careproducts, with operations based in the US and Canada, and sales worldwide. Thecompany recently launched its MEDIHONEY(TM) Wound & Burn dressings with ActiveLeptospermum Honey. The Company has also obtained FDA clearance to market andsell its MOBILITY-1(TM) boot and compressor device for the treatment of venousulcers, lymphedema, and other conditions that require compression therapy. Formore information about Derma Sciences, Inc., visit its home page on theInternet at http://www.dermasciences.com.

About the APWCA

The American Professional Wound Care Association (APWCA) is a hybridnon-profit organization whose mem
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Insulet Corporation to Report Fourth Quarter and F...
S
IDM Pharma Announces Compliance With NASDAQ Minimu...